Publications by authors named "Zi Yun Li"

Article Synopsis
  • Cadonilimab, first approved bi-specific antibody in June 2022 for certain cancers, features a modified Fc structure to lower side effects.
  • A case of toxic epidermal necrolysis (TEN)-like reactions was reported in a patient treated for hepatocellular carcinoma with Cadonilimab, Lenvatinib, and chemoembolization, with successful resolution following Adalimumab treatment.
  • This highlights the rare risk of Cadonilimab inducing TEN and suggests that Adalimumab may be an effective treatment for cases where TEN occurs as a result of Cadonilimab.
View Article and Find Full Text PDF

Introduction: To date, there is no standard treatment for Morbihan disease. Several studies have reported that Morbihan disease responds well to systemic corticosteroids (prednisone and prednisolone), systemic antibiotics (tetracyclines), antihistamines (ketotifen) and surgical therapy (Lymphaticovenous anastomosis). To our knowledge, Tofacitinib, as a Janus-activated kinase (JAK) inhibitor, plays a vital role in the treatment of inflammatory and autoimmune disorders.

View Article and Find Full Text PDF

Purpose: Patients with esophageal cancer experience physical and psychosocial difficulties after surgery. Understanding their unmet supportive care needs could help medical staff in providing high quality of care. This study aimed to gain insights into the supportive care needs of discharged patients with esophageal cancer after esophagectomy.

View Article and Find Full Text PDF

Trimethylamine N-oxide (TMAO), a gut microbiota-dependent metabolite, has been shown to aggravate cardiovascular disease. However, the mechanisms of TMAO in the setting of cardiovascular disease progress remain unclear. Here, we aim to investigate the effects of TMAO on atherosclerosis (AS) development and the underlying mechanisms.

View Article and Find Full Text PDF